274 related articles for article (PubMed ID: 15791814)
1. [Progress in therapeutic strategy for malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
[TBL] [Abstract][Full Text] [Related]
2. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
4. [The choice of second-line chemotherapy for malignant lymphoma].
Ikeda T; Hotta T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):6-10. PubMed ID: 15675573
[TBL] [Abstract][Full Text] [Related]
5. [Medicinal therapy of malignant lymphomas].
Aul C; Schroeder M; Giagounidis A
Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
9. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
10. [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Ogura M
Rinsho Ketsueki; 2008 Oct; 49(10):1434-50. PubMed ID: 18833928
[No Abstract] [Full Text] [Related]
11. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
Held G; Schubert J; Reiser M; Pfreundschuh M;
Semin Hematol; 2006 Oct; 43(4):221-9. PubMed ID: 17027656
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in high-grade lymphoma.
Zwick C; Murawski N; Pfreundschuh M;
Semin Hematol; 2010 Apr; 47(2):148-55. PubMed ID: 20350662
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma.
Shikama N; Oguchi M; Isobe K; Nakamura K; Tamaki Y; Hasegawa M; Kodaira T; Sasaki S; Kagami Y;
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):217-22. PubMed ID: 16814951
[TBL] [Abstract][Full Text] [Related]
16. New treatment strategies for aggressive lymphoma.
Younes A
Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
[TBL] [Abstract][Full Text] [Related]
17. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1724-30. PubMed ID: 7574802
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
20. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
